Domain: gene.com
Stories and comments across the archive that link to gene.com.
Comments · 9
-
Re:Rising Tide Lifts All Boats Falling Tide Sinks
Cancer --> paradigm targeted immunotherapy --> CLEOPATRA
http://www.gene.com/media/pres...Cardiovascular --> paradigm mAb targeted cholesterol knockdown --> Regeneron
http://www.fiercebiotech.com/s...Advanced genomic typing of chronic conditions plus harnessing of an arsenal of immunotherapeutic approaches coupled with targeted inhibitors could IMHO pave the way to lasting benefit for a good number of patients. This is 21st century impact medicine...it took a while to develop
You asked, I have my delusional opinions too. The grant money is indeed hard to come by.
-
Re:Will the reality distortion field last?
These are pretty conventional corporate appointments,
Fool! He's head of Genetech. The first Biotech company. They're so old they managed to get "gene.com".
Think cloning.
Think Steve.
Think how much DNA of his is floating around in the lab.
Profit!
-
Re:What's a virus?
Michel Colman? Do I know you from somewhere ?
-
Re:As a Mac admin, I agree.
-
Meanwhile, at certain biotechs...
I wonder how http://www.gene.com/gene/products/education/vascular/amd.htmlGenentech feels about this one? Their Lucentis treatment for AMD is delivered by inter-ocular injection, to which I say "thanks, but no thanks!"
-
Re:Well...
Notable exception:
Art Levinson of Genentech. A serious scientist and a serious CEO.
Stock chart. -
Re:Real world stories
Well, theres Apple, of course. And Pixar. And the Virginia Tech supercluster, and the majority of genetic research/biotech labs, like the Whitehead Institute, BioGen and Genentech. Then there's Staples corporate headquarters. Those are the ones I know of off the top of my head.
-
Re:Keeping your employees happy...
I used to work for Genentech, and they did something similar for their researchers.
Only for the lab researchers IIRC and in any case not for people as low on the org chart as I was... but still, they let those people use a significant portion of their time, and the company's resources (equipment, lab assistants, etc) pursuing whatever they thought was interesting.
Of course the company owned the results. At least one of their major products came from this direction.
They also had a nice sabbatical program. In short, they went pretty far to keep their "high-value" employees happy, and it paid off for them big-time.
-
Article availabe here
Just a small quibble:
First: the article was published in Science and is available here.
And you're very right in pointing out that of the vast number of antibody-directed cancer therapies mentioned in the literature, almost all have failed in people. However, there are a few successes - Mylotarg, Ontak, Herceptin, and Rituxan spring to mind. In fact, the Herceptin antibody was one of the antibodies used in this study - which increases the odds of clinical relevance.
Hasta.